 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Doxil- Doxil
- Ortho Biotech Brand of Doxorubicin Hydrochloride
Doxorubicin NC- Doxorubicin NC
- Neocorp Brand of Doxorubicin Hydrochloride
Doxotec- Doxotec
- Columbia Brand of Doxorubicin Hydrochloride
Farmiblastina- Farmiblastina
- Kenfarma Brand of Doxorubicin Hydrochloride
Myocet- Myocet
- Elan Brand of Doxorubicin Hydrochloride
Onkodox- Onkodox
- Onkoworks Brand of Doxorubicin Hydrochloride
Ribodoxo- Ribodoxo
- ribosepharm Brand of Doxorubicin Hydrochloride
Rubex- Rubex
- Bristol-Myers Squibb Brand of Doxorubicin Hydrochloride
Adriblastin- Adriblastin
- Pfizer Brand of Doxorubicin Hydrochloride
- Adriblastina
- Adriblastine
- Adriablastin
- Adriablastine
Adriamycin- Adriamycin
- Bedford Brand of Doxorubicin Hydrochloride
Adrimedac- Adrimedac
- medac Brand of Doxorubicin Hydrochloride
Caelyx- Caelyx
- Schering Brand of Doxorubicin Hydrochloride
- Schering-Plough Brand of Doxorubicin Hydrochloride
- Essex Brand of Doxorubicin Hydrochloride
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
- cell pharm Brand of Doxorubicin Hydrochloride
Doxolem- Doxolem
- Lemery Brand of Doxorubicin Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in UAMS Profiles by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2021 | 3 | 5 | 8 | | 2020 | 2 | 6 | 8 | | 2019 | 2 | 4 | 6 | | 2018 | 4 | 3 | 7 | | 2017 | 6 | 2 | 8 | | 2016 | 5 | 1 | 6 | | 2015 | 4 | 4 | 8 | | 2014 | 1 | 6 | 7 | | 2013 | 3 | 7 | 10 | | 2012 | 4 | 2 | 6 | | 2011 | 1 | 3 | 4 | | 2010 | 1 | 4 | 5 | | 2009 | 2 | 5 | 7 | | 2008 | 1 | 6 | 7 | | 2007 | 2 | 5 | 7 | | 2006 | 3 | 3 | 6 | | 2005 | 2 | 5 | 7 | | 2004 | 1 | 2 | 3 | | 2003 | 4 | 7 | 11 | | 2002 | 3 | 5 | 8 | | 2001 | 1 | 1 | 2 | | 2000 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 1998 | 1 | 3 | 4 | | 1996 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1991 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles over the past ten years.
-
Desai VG, Vijay V, Lee T, Han T, Moland CL, Phanavanh B, Herman EH, Stine K, Fuscoe JC. MicroRNA-34a-5p as a promising early circulating preclinical biomarker of doxorubicin-induced chronic cardiotoxicity. J Appl Toxicol. 2022 09; 42(9):1477-1490.
-
Desai VG, Vijay V, Han T, Moland CL, Phanavanh B, Lee T, Davis KJ, Muskhelishvili L, Stine KC, Fuscoe JC. Doxorubicin-induced delayed-onset subclinical cardiotoxicity in mice. J Appl Toxicol. 2022 05; 42(5):778-792.
-
Badgwell B. Is PIPAC a New Summit for Peritoneal Disease Treatment or are we Lost in the Snowstorm? Ann Surg Oncol. 2022 01; 29(1):13-14.
-
Mohan M, Meek JC, Meek ME, Broadwater R, Alapat D, van Rhee F. Combinatorial treatment for unresectable unicentric Castleman disease. Eur J Haematol. 2021 Oct; 107(4):484-488.
-
Hussein UK, Ahmed AG, Song Y, Kim KM, Moon YJ, Ahn AR, Park HS, Ahn SJ, Park SH, Kim JR, Jang KY. CK2a/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway. Cells. 2021 07 13; 10(7).
-
Bagchi AK, Malik A, Akolkar G, Zimmer A, Belló-Klein A, De Angelis K, Jassal DS, Fini MA, Stenmark KR, Singal PK. Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Biochim Biophys Acta Mol Cell Res. 2021 06; 1868(7):119039.
-
Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 08; 194(3):496-507.
-
Brown T, McElroy T, Simmons P, Walters H, Ntagwabira F, Wang J, Byrum SD, Allen AR. Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide. Brain Res. 2021 06 01; 1760:147397.
-
Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021 03 01; 106(3):730-735.
-
Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol. 2021 02; 192(3):e73-e77.
-
Zhang Z, Ha SH, Moon YJ, Hussein UK, Song Y, Kim KM, Park SH, Park HS, Park BH, Ahn AR, Lee SA, Ahn SJ, Kim JR, Jang KY. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma. J Exp Clin Cancer Res. 2020 Nov 17; 39(1):247.
-
Ramos JC, Sparano JA, Chadburn A, Reid EG, Ambinder RF, Siegel ER, Moore PC, Rubinstein PG, Durand CM, Cesarman E, Aboulafia D, Baiocchi R, Ratner L, Kaplan L, Capoferri AA, Lee JY, Mitsuyasu R, Noy A. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020 09 10; 136(11):1284-1297.
-
Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020 08 27; 136(9):1091-1104.
-
Duong VH, Begna KH, Kashanian S, Sweet K, Wang ES, Caddell R, Shafer DA, Singh ZN, Baer MR, Al-Kali A. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Ann Hematol. 2020 Sep; 99(9):2119-2124.
-
Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kortüm KM. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Cancer Med. 2020 08; 9(16):5819-5826.
-
McElroy T, Brown T, Kiffer F, Wang J, Byrum SD, Oberley-Deegan RE, Allen AR. Assessing the Effects of Redox Modifier MnTnBuOE-2-PyP 5+ on Cognition and Hippocampal Physiology Following Doxorubicin, Cyclophosphamide, and Paclitaxel Treatment. Int J Mol Sci. 2020 Mar 09; 21(5).
-
He Y, Li W, Lv D, Zhang X, Zhang X, Ortiz YT, Budamagunta V, Campisi J, Zheng G, Zhou D. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell. 2020 03; 19(3):e13117.
-
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
-
Stolarz AJ, Sarimollaoglu M, Marecki JC, Fletcher TW, Galanzha EI, Rhee SW, Zharov VP, Klimberg VS, Rusch NJ. Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow. J Pharmacol Exp Ther. 2019 11; 371(2):278-289.
-
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, Lee ST, Kocoglu MH, Shanholtz C, Badros A, Hardy N, Yared J, Rapoport AP, Dahiya S. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019 10; 94(10):E273-E275.
-
Sun Y, Nemec-Bakk AS, Mallik AU, Bagchi AK, Singal PK, Khaper N. Blueberry extract attenuates doxorubicin-induced damage in H9c2 cardiac cells 1. Can J Physiol Pharmacol. 2019 Sep; 97(9):880-884.
-
Arif E, Solanki AK, Srivastava P, Rahman B, Fitzgibbon WR, Deng P, Budisavljevic MN, Baicu CF, Zile MR, Megyesi J, Janech MG, Kwon SH, Collier J, Schnellmann RG, Nihalani D. Mitochondrial biogenesis induced by the ß2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 2019 09; 96(3):656-673.
-
Kessler SM, Hosseini K, Hussein UK, Kim KM, List M, Schultheiß CS, Schulz MH, Laggai S, Jang KY, Kiemer AK. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival. Cell Physiol Biochem. 2019; 52(4):787-801.
-
Ayesh Haj Yousef MH, Eyadeh A, Rawashdeh RA, Khasawneh R, Saleh JA, Jibreel MJ. Vinblastine-induced posterior reversible encephalopathy syndrome. J Oncol Pharm Pract. 2019 Dec; 25(8):2019-2022.
-
Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152.
-
Kumari M, Purohit MP, Patnaik S, Shukla Y, Kumar P, Gupta KC. Curcumin loaded selenium nanoparticles synergize the anticancer potential of doxorubicin contained in self-assembled, cell receptor targeted nanoparticles. Eur J Pharm Biopharm. 2018 Sep; 130:185-199.
-
Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, Hussein UK, Zhang Z, Park HS, Park BH, Moon WS, Kim JR, Jang KY. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. J Exp Clin Cancer Res. 2018 May 21; 37(1):107.
-
Flanigan TJ, Anderson JE, Elayan I, Allen AR, Ferguson SA. Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment. Toxicol Sci. 2018 04 01; 162(2):462-474.
-
Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 04 01; 29(4):917-923.
-
Bose C, Awasthi S, Sharma R, Beneš H, Hauer-Jensen M, Boerma M, Singh SP. Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model. PLoS One. 2018; 13(3):e0193918.
-
Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):316-324.
-
Yu LR, Cao Z, Makhoul I, Daniels JR, Klimberg S, Wei JY, Bai JP, Li J, Lathrop JT, Beger RD, Todorova VK. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Exp Biol Med (Maywood). 2018 02; 243(3):248-255.
-
Purohit MP, Verma NK, Kar AK, Singh A, Ghosh D, Patnaik S. Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells. ACS Appl Mater Interfaces. 2017 Oct 25; 9(42):36493-36512.
-
Nima ZA, Alwbari AM, Dantuluri V, Hamzah RN, Sra N, Motwani P, Arnaoutakis K, Levy RA, Bohliqa AF, Nedosekin D, Zharov VP, Makhoul I, Biris AS. Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. J Appl Toxicol. 2017 Dec; 37(12):1370-1378.
-
Liu Z, Nemec-Bakk A, Khaper N, Chen A. Sensitive Electrochemical Detection of Nitric Oxide Release from Cardiac and Cancer Cells via a Hierarchical Nanoporous Gold Microelectrode. Anal Chem. 2017 08 01; 89(15):8036-8043.
-
Akolkar G, da Silva Dias D, Ayyappan P, Bagchi AK, Jassal DS, Salemi VMC, Irigoyen MC, De Angelis K, Singal PK. Vitamin C mitigates oxidative/nitrosative stress and inflammation in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2017 Oct 01; 313(4):H795-H809.
-
Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253.
-
Todorova VK, Makhoul I, Dhakal I, Wei J, Stone A, Carter W, Owen A, Klimberg VS. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. Oncol Res. 2017 Sep 21; 25(8):1223-1229.
-
Todorova VK, Makhoul I, Wei J, Klimberg VS. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients. Ann Clin Lab Sci. 2017 Mar; 47(2):115-119.
-
Akolkar G, Bagchi AK, Ayyappan P, Jassal DS, Singal PK. Doxorubicin-induced nitrosative stress is mitigated by vitamin C via the modulation of nitric oxide synthases. Am J Physiol Cell Physiol. 2017 Apr 01; 312(4):C418-C427.
-
Verma NK, Purohit MP, Equbal D, Dhiman N, Singh A, Kar AK, Shankar J, Tehlan S, Patnaik S. Targeted Smart pH and Thermoresponsive N,O-Carboxymethyl Chitosan Conjugated Nanogels for Enhanced Therapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells. Bioconjug Chem. 2016 Nov 16; 27(11):2605-2619.
-
Todorova VK, Makhoul I, Siegel ER, Wei J, Stone A, Carter W, Beggs ML, Owen A, Klimberg VS. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. PLoS One. 2016; 11(8):e0160224.
-
Montales MT, Melnyk SB, Liu SJ, Simmen FA, Liu YL, Simmen RC. Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice. Endocr Relat Cancer. 2016 09; 23(9):677-90.
-
Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol. 2016 06; 39(3):248-54.
-
Mallick N, Anwar M, Asfer M, Mehdi SH, Rizvi MMA, Panda AK, Talegaonkar S, Ahmad FJ. Chondroitin sulfate-capped super-paramagnetic iron oxide nanoparticles as potential carriers of doxorubicin hydrochloride. Carbohydr Polym. 2016 Oct 20; 151:546-556.
-
Leach JC, Wang A, Ye K, Jin S. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery. Int J Mol Sci. 2016 Mar 14; 17(3):380.
-
Schnackenberg LK, Pence L, Vijay V, Moland CL, George N, Cao Z, Yu LR, Fuscoe JC, Beger RD, Desai VG. Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice. J Appl Toxicol. 2016 11; 36(11):1486-95.
-
Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res. 2016 Jan 15; 22(2):328-36.
-
Zhang W, Deng J, Sunkara M, Morris AJ, Wang C, St Clair D, Vore M. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice. J Pharmacol Exp Ther. 2015 Nov; 355(2):280-7.
-
Deng J, Coy D, Zhang W, Sunkara M, Morris AJ, Wang C, Chaiswing L, St Clair D, Vore M, Jungsuwadee P. Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice. J Pharmacol Exp Ther. 2015 Nov; 355(2):272-9.
-
Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 2015 Jul 29; 15:555.
-
Singh P, Sharma R, McElhanon K, Allen CD, Megyesi JK, Beneš H, Singh SP. Sulforaphane protects the heart from doxorubicin-induced toxicity. Free Radic Biol Med. 2015 Sep; 86:90-101.
-
Abdallah AO, Bansal M, Kemp SA, Schichman SA, Xiang Z. A unique presentation of unilateral pleural effusion in a patient with a high-grade plasma cell neoplasm. Leuk Lymphoma. 2015; 56(10):2989-91.
-
Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 09; 126(2):160-6.
-
Mohamed RH, Karam RA, Hagrass HA, Amer MG, Abd El-Haleem MR. Anti-apoptotic effect of spermatogonial stem cells on doxorubicin-induced testicular toxicity in rats. Gene. 2015 Apr 25; 561(1):107-14.
-
Marrero L, Wyczechowska D, Musto AE, Wilk A, Vashistha H, Zapata A, Walker C, Velasco-Gonzalez C, Parsons C, Wieland S, Levitt D, Reiss K, Prakash O. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia. 2014 Oct; 16(10):874-82.
-
Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
-
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014 Sep 02; 64(9):938-45.
-
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
-
Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer. 2014 Jul 15; 120(14):2122-9.
-
Lapa C, Knott M, Rasche L, Herrmann K, Buck AK, Rosenwald A. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. Eur J Haematol. 2014 Dec; 93(6):545-6.
-
Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014 Jun; 93(6):1001-5.
-
Datta S, Parajuli N, Tymoszuk P, Ottina E, Parson W, Sgonc R, Villunger A, Doppler W. Replenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1. J Leukoc Biol. 2014 Jun; 95(6):853-66.
-
Beneš H, Vuong MK, Boerma M, McElhanon KE, Siegel ER, Singh SP. Protection from oxidative and electrophilic stress in the Gsta4-null mouse heart. Cardiovasc Toxicol. 2013 Dec; 13(4):347-56.
-
Lee MT, Ho SM, Tarapore P, Chung I, Leung YK. Estrogen receptor ß isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. Neoplasia. 2013 Nov; 15(11):1262-71.
-
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 Nov 07; 122(19):3251-62.
-
Chekhun VF, Lukyanova NY, Burlaka CA, Bezdenezhnykh NA, Shpyleva SI, Tryndyak VP, Beland FA, Pogribny IP. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol. 2013 Nov; 43(5):1481-6.
-
Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013 Oct; 43(10):2718-29.
-
Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol. 2013 Sep; 162(5):678-83.
-
Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):502-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|